Institutional investors “should be thoughtful about balancing risk and reward” as they deploy more capital into private markets that present liquidity and valuation challenges, according to the deputy CIO of Australia’s Future Fund.
LPs that have more capital to invest but fewer attractive opportunities to invest in are naturally drawn to the potentially higher returns of private markets, Wendy Norris told the Australian Investment...
Increased climate change awareness on a corporate level is leading to more investment – either direct or through funds – in start-ups that offer mitigation solutions. Asia is a key geography
Healthcare-focused Panacea Venture has led a $40 million Series C round for China’s XWPharma, a neurobiology-focused biotech developer previously known as XW Laboratories.
Kyee Technology, a Chinese digital medical platform has raised RMB430 million ($64 million) in a Series D round led by Tencent Holdings. Other investors include Longmen Capital, Dyee Capital and Royal Sea Capital.
Biocytogen, a Chinese contract research organization (CRO) that provides genetically-modified mice for drug testing, has raised RMB970 million ($143 million) in an extended tranche of Series D funding.